Canada’s brand-name pharmaceutical manufacturing sector supplies the healthcare system with innovative treatments relied upon by hospitals, public and private insurers, and patients with complex conditions.
With $7.5B in revenue in 2024, the sector employs over 17,000 highly qualified professionals across nearly 700 facilities nationwide.
Demand is fueled by an aging population, the rise of biologic therapies, and the need for manufacturers to continuously renew their portfolios in the face of competition from generics and biosimilars.
The following indicators provide a quick overview of the sector’s scale, profitability, and specialization.
Total value of brand-name drug sales in the country.
Profitability maintained despite growing pressure from generics, thanks to the added value of innovative therapies.
Antineoplastic and immunomodulating agents account for nearly half of industry revenue, reflecting major investments in cancer treatment.
By 2029, an average annual growth rate of 2% is expected, driven by:
Manufacturers that secure a diversified pipeline, form research partnerships, and expand their international presence will be best positioned to offset patent expirations and meet the pricing demands of insurance plans.
The following indicators provide a quick overview of the sector’s scale, profitability, and specialization.
Parlons-en. Notre équipe vous aide à structurer votre réflexion et à prendre des décisions éclairées, sans engagement.